![](https://library.celltelligence.com/wp-content/uploads/2024/03/Screenshot-2024-03-20-at-17.49.51.png)
$0
Thoughts on the FDA ODAC Recommending Carvykti and Abecma in Earlier Lines of MM
On Friday, March 15, JNJ (press release) and Legend (press release) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended Carvykti (BCMA CAR-T) for the treatment of adult patients with r/r MM who have received at least one prior LoT including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and are refractory to lenalidomide.